Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on January 19, 2023, at 2:30 p.m. ET. The company's CEO, Sean McCarthy, will lead the presentation, which can be accessed via a live webcast on CytomX’s website, with an archived replay available for 30 days. CytomX specializes in conditionally activated biologics, focusing on innovative cancer treatments, supported by its Probody® technology platform. The company’s pipeline includes seven therapeutic candidates, collaborating with major partners like AbbVie and Amgen. For more information, visit www.cytomx.com.
CytomX Therapeutics (Nasdaq: CTMX) has announced encouraging results from its Phase 2 cohort expansion study of CX-2029, showing a 21% objective response rate in squamous esophageal cancer and a 10% response rate in squamous non-small cell lung cancer (sqNSCLC) among heavily pre-treated patients. The company is collaborating with Moderna to develop mRNA-based therapeutics and anticipates filing two INDs for new wholly owned programs in 2023. CytomX also plans to determine next steps for CX-2029 with AbbVie this year, while continuing research in T-cell bispecifics.
CytomX Therapeutics (NASDAQ: CTMX) and Moderna (NASDAQ: MRNA) have announced a collaboration to create mRNA-based therapeutics using CytomX's Probody® platform. CytomX will receive $35 million upfront, including $5 million for research funding, with potential future payments of up to $1.2 billion in development milestones and royalties on commercialized products. The partnership aims to develop conditionally activated therapies for various diseases, enhancing both companies' therapeutic pipelines.
CytomX Therapeutics (Nasdaq: CTMX) announced plans to share its 2023 pipeline priorities and provide a data update for the CX-2029 Phase 2 cohort expansion study on January 5, 2023. The updates will follow a conference call at 5:00 p.m. ET. CytomX, a clinical-stage oncology biopharmaceutical company, focuses on developing conditionally activated treatments through its Probody® technology. Its pipeline includes ADCs and T-cell engaging bispecific antibodies, with CX-2029 currently in development, showing promise for patients with squamous non-small cell lung cancer.
CytomX Therapeutics (Nasdaq: CTMX) will have its CEO, Sean McCarthy, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. ET. Attendees can watch a live webcast on CytomX's website, and an archived replay will be available for 30 days post-event. The company specializes in conditionally activated oncology therapeutics and has a diverse pipeline including investigational therapies like CX-2029 and collaborations with AbbVie and Amgen. For further details, visit www.cytomx.com.
CytomX Therapeutics (CTMX) announced that Phase 2 data for CX-2009, an ADC targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8, 2022. The data focuses on praluzatamab ravtansine for advanced HR+/HER2- breast cancer and triple-negative breast cancer. Despite previous decisions not to advance the program without a partner, the research has provided valuable insights for future Probody therapeutic candidates. The poster session is scheduled for 7:00 am - 8:15 am CT, featuring Dr. Kathy Miller as the presenting author.
CytomX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop bispecific cancer therapies leveraging CytomX's Probody® platform and Regeneron's Veloci-Bi® technology. CytomX will receive a $30 million upfront payment and could earn up to $2 billion in future milestone payments related to research and commercialization. The partnership aims to create conditionally activated therapies designed to minimize off-target effects, potentially benefiting tumor types unresponsive to current immunotherapy approaches.
Regeneron Pharmaceuticals and CytomX Therapeutics have entered a significant collaboration to develop next-generation bispecific immunotherapies. CytomX will receive an upfront payment of $30 million and could earn up to $2 billion in future milestones. The collaboration focuses on utilizing CytomX's Probody® technology and Regeneron's Veloci-Bi® platform to create therapies that activate specifically in tumor environments, potentially improving treatment efficacy and reducing side effects. The partnership aims to expand cancer treatment options significantly.
CytomX Therapeutics (CTMX) reported its Q3 2022 financial results and business updates, highlighting advancements in its oncology pipeline. The company is progressing on CX-2051 and CX-801, both slated for IND submissions in 2023. CX-904 is currently in Phase 1, while collaborations with Bristol Myers Squibb on BMS-986249 and AbbVie on CX-2029 continue in Phase 2. Financially, cash reserves decreased to $194.3 million from $305.2 million year-over-year, with revenue of $16.9 million. R&D expenses rose to $30.4 million, reflecting restructuring expenses.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming presentation of preclinical data for CX-801, a masked interferon alpha-2b therapeutic candidate, at the SITC Annual Meeting in Boston. CX-801 aims to improve tolerability and efficacy in treating tumors by leveraging a favorable therapeutic index. The company plans to file an IND for CX-801 in the second half of 2023, with ongoing exploration of its potential in both responsive and non-responsive tumor types. The presentation is scheduled for November 10-11, 2022, detailing the benefits of CX-801 combined with PD-L1 blockade.